Osteonecrosis of the jaws induced by anti-RANK ligand therapy

被引：154

作者：

Taylor, K. H. ^{[1
]}

Middlefell, L. S. ^{[1
]}

Mizen, K. D. ^{[1
]}

机构：

[1] Pinderfields Gen Hosp, Wakefield WF1 4DF, W Yorkshire, England

来源：

BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY | 2010年 / 48卷 / 03期

关键词：

Osteonecrosis; Anti-RANKL; Denosumab; POSTMENOPAUSAL WOMEN; BREAST-CANCER; PAMIDRONATE; EFFICACY;

D O I：

10.1016/j.bjoms.2009.08.030

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

Since the introduction of bisphosphonates to treat diseases that affect remodelling of bone, increasing numbers of patients with bisphosphonate-related osteonecrosis of the jaws have been reported; the number is currently unknown. Recently anti-RANKL agents (receptor activator of nuclear factor-kappa B ligand) such as denosumab (Prolia (TM), Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases. We report a case of osteonecrosis that was induced by anti-RANKL therapy. To our knowledge this is the first case to have been induced by these agents. (C) 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

引用

页码：221 / 223

页数：3

共 8 条

[1] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].

Anderson, DM ;

Maraskovsky, E ;

Billingsley, WL ;

Dougall, WC ;

Tometsko, ME ;

Roux, ER ;

Teepe, MC ;

DuBose, RF ;

Cosman, D ;

Galibert, L .

NATURE, 1997, 390 (6656) :175-179

[2] A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].

Bekker, PJ ;

Holloway, DL ;

Rasmussen, AS ;

Murphy, R ;

Martin, SW ;

Leese, PT ;

Holmes, GB ;

Dunstan, CR ;

DePaoli, AM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066

[3] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, MJ ;

Blacklock, HA ;

Bell, R ;

Simeone, J ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493

[4] Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws [J].

Herbozo, Percival J. ;

Briones, Daniel L. ;

Ferres, Alvaro J. ;

Torrealba, Ramon L. .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2007, 65 (08) :1650-1654

[5] Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases [J].

Hortobagyi, GN ;

Theriault, RL ;

Porter, L ;

Blayney, D ;

Lipton, A ;

Sinoff, C ;

Wheeler, H ;

Simeone, JF ;

Seaman, J ;

Knight, RD ;

Heffernan, M ;

Reitsma, DJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (24) :1785-1791

[6] Denosumab in postmenopausal women with low bone mineral density [J].

McClung, MR ;

Lewiecki, EM ;

Cohen, SB ;

Bolognese, MA ;

Woodson, GC ;

Moffett, AH ;

Peacock, M ;

Miller, PD ;

Lederman, SN ;

Chesnut, CH ;

Lain, D ;

Kivitz, AJ ;

Holloway, DL ;

Zhang, C ;

Peterson, MC ;

Bekker, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :821-831

[7] Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy [J].

Sauty, A ;

Pecherstorfer, M ;

ZimmerRoth, I ;

Fioroni, P ;

Juillerat, L ;

Markert, M ;

Ludwig, H ;

Leuenberger, P ;

Burckhardt, P ;

Thiebaud, D .

BONE, 1996, 18 (02) :133-139

[8] Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions:: A randomized, placebo-controlled trial [J].

Theriault, RL ;

Lipton, A ;

Hortobagyi, GN ;

Leff, R ;

Glück, S ;

Stewart, JF ;

Costello, S ;

Kennedy, I ;

Simeone, J ;

Seaman, JJ ;

Knight, RD ;

Mellars, K ;

Heffernan, M ;

Reitsma, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :846-854

← 1 →